Veracyte | VCYT - Cost Of Sales

Stock Price
36.59
Daily Change
-2.16 -5.57%
Monthly
-4.91%
Yearly
5.26%
Q1 Forecast
34.53

Veracyte reported $39.28M in Cost of Sales for its fiscal quarter ending in December of 2025.





Cost Of Sales Change Date
Agenus USD 137K 19K Mar/2025
Agilent USD 852M 19M Dec/2025
Anika Therapeutics USD 11.49M 35.48M Mar/2025
Bruker USD 528M 46.9M Dec/2025
Exact Sciences USD 266.81M 18.18M Sep/2025
Heron Therapeutics USD 9.46M 1.61M Sep/2024
Illumina USD 400M 49M Dec/2025
Intrexon USD 1.01M 344K Jun/2024
Karyopharm Therapeutics USD 37.43M 2.41M Sep/2024
Laboratory Of America USD 2.6B 56.8M Dec/2025
Ligand Pharmaceuticals USD 11.9M 733K Sep/2025
Myriad Genetics USD 61.9M 600K Sep/2025
Rigel Pharmaceuticals USD 8.03M 5.22M Sep/2024
Roche Holding CHF 8.48B 4.61B Dec/2025
Sangamo BioSciences 2.42M 1.11M Jun/2024
Siemens EUR 11.51B 1.82B Dec/2025
Sonic Healthcare AUD 751.66M 801.13M Dec/2024
Thermo Fisher Scientific USD 7.58B 674M Dec/2025
Veracyte USD 39.28M 1.93M Dec/2025
Waters USD 374.94M 47.13M Dec/2025